Latest Earnings Recovery News

Coventry Group’s Q1 FY27 EBITDA nearly doubled to A$5.4 million as cost reductions and margin gains began to outweigh modest sales growth. Leverage has also halved from its March peak, although the strategic review has yet to produce a transaction.

Bubs Australia delivered 9.2% revenue growth and a sharp underlying EBITDA improvement in FY26, but statutory losses, weaker margins and negative operating cash flow expose the cost of its expansion. Permanent US FDA authorisation removes a major regulatory hurdle, while the annual report still flags material uncertainty around ongoing funding and cash generation.

Medical Developments International returned to EBIT profitability in FY26 as Penthrox volumes strengthened across Australian hospitals and Europe. The company now faces the less glamorous test of converting regulatory progress into repeatable demand while absorbing weaker Respiratory sales and new amortisation costs.

Trajan Scientific and Medical (ASX:TRJ) says FY27 has begun with improving revenue, quarterly nEBITDA of about A$3.5 million and a A$1.6 million reduction in net debt. The company expects mid-single-digit organic revenue growth and double-digit nEBITDA growth for the year, although its latest quarterly figures remain unaudited.

Savana US Small Caps Active ETF (ASX:SVNP) fell 7.65% in September, trailing the S&P SmallCap 600 by 4.92 percentage points as higher US bond yields and a concentrated AI rally split the market. The manager says its valuation discipline kept it away from the month’s strongest semiconductor performers, while highlighting a 52% gain from its Everforth investment.

Camplify Holdings cut its FY26 net loss by 95% and returned to profit in the second half as cost reductions and MyWay Mutual reshaped the business. The turnaround remains incomplete, with negative operating cash flow, a net current liability position and an auditor’s material uncertainty warning.

Buxton Resources has returned to profit after selling its 49% Copper Wolf joint venture interest to IGO for A$5.91 million. The transaction lifted cash and term deposit investments to A$7.39 million, but the explorer remains dependent on capital and future discoveries rather than recurring earnings.

The Warehouse Group (NZX:WHS) returned to profit in FY26 and cut net debt by more than 80%, despite broadly flat comparable sales. The recovery came with a clear catch: The Warehouse brand remains loss-making and shareholders will receive no final dividend.

Beacon Minerals has reported a sharp FY2026 recovery, underpinned by higher gold revenue, Lady Ida production and a substantial increase in the Iguana Ore Reserve. The headline profit includes a sizeable asset-sale gain, leaving the next test focused on recurring mine performance.

Alfabs Australia’s FY26 reset preserved free cash flow despite a sharp earnings decline, while Mining growth and debt refinancing form the bridge to a potential dividend restart. The company enters FY27 leaner, but the plan still depends on execution, cash conversion and Phase II debt restructuring.

Ramsay Health Care delivered stronger FY26 earnings, a higher fully franked dividend and improved Funding Group leverage as it prepares to separate Ramsay Santé. The proposed demerger remains conditional, but the company has set a clear timetable for the next phase of its portfolio reshaping.

FFI Holdings lifted underlying pre-tax profit 6.8% to $4.62 million in FY2026, while food manufacturing delivered stronger earnings and operating cash flow rebounded sharply. The ASX-listed group now plans a $5.1 million factory and warehouse development in Cockburn, funded from existing resources.